- Abzena’s AbZelectPRO platform cuts development timelines by over 30%, delivering results within 10 weeks.
- The platform boosts protein production to up to 8g/L, improving efficiency and reducing costs for biopharma customers.
Abzena, a global CDMO specialising in complex biologics and bioconjugates, has introduced its enhanced mammalian cell line development platform, AbZelectPRO, as a standard offering for all customers. The platform now significantly reduces development timelines by more than 30%, enabling biopharma companies to transition from DNA to research cell bank (RCB) in just 10 weeks. It also increases protein production levels to up to 8g/L, offering a streamlined approach for developing therapeutic proteins.
AbZelectPRO combines ProteoNic’s 2G UNic vector technology with Abzena’s CHO cell line, enhancing the frequency of high-producing clones for therapeutic proteins and recombinant vaccines. This collaboration not only increases production efficiency but also lowers the cost of goods, benefitting biopharma customers by making the process faster and more cost-effective.
Simon Keen, VP of Cell Line Development at Abzena, said, “We’ve fine-tuned AbZelectPRO over the past 10 months, and it has consistently shown improved cycle times and productivity, giving our customers more chances of clinical success.”
The platform’s integration of the 2G UNic vector technology has proven to enhance expression levels for difficult-to-express proteins, including bispecifics and fusion proteins. It also ensures stability across more than 60 generations, boosting yields for challenging modalities.
Frank Pieper, CEO of ProteoNic, added, “Integrating 2G UNic technology into AbZelectPRO enhances productivity, especially for tough expression challenges like bispecifics.”
Overview of outsourcing trends 
